Axsome Therapeutics, Inc. (AXSM)
NASDAQ$124.76
Market Cap
$6.08B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
476 of 924
Rank in Industry
279 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
AXSM Insider Trading Activity
AXSM Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $10,261,752 | 8 | 100 |
Related Transactions
| Coleman Mark | director | 0 | $0 | 2 | $789,107 | $-789,107 |
| Saad Mark E | director | 0 | $0 | 1 | $1.01M | $-1.01M |
| Pizzie Nick | Chief Financial Officer | 0 | $0 | 2 | $1.95M | $-1.95M |
| Jacobson Mark L. | Chief Operating Officer | 0 | $0 | 3 | $6.52M | $-6.52M |
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly …
Insider Activity of Axsome Therapeutics, Inc.
Over the last 12 months, insiders at Axsome Therapeutics, Inc. have bought $0 and sold $10.26M worth of Axsome Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Axsome Therapeutics, Inc. have bought $242,389 and sold $6.92M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,950 shares for transaction amount of $147,350 was made by JEFFS ROGER (director) on 2021‑11‑19.
List of Insider Buy and Sell Transactions, Axsome Therapeutics, Inc.
| 2025-02-14 | Sale | Pizzie Nick | Chief Financial Officer | 3,000 0.0062% | $131.07 | $393,210 | -4.17% | |
| 2025-02-13 | Sale | Pizzie Nick | Chief Financial Officer | 12,000 0.0244% | $129.86 | $1.56M | -4.53% | |
| 2024-09-11 | Sale | Saad Mark E | director | 11,016 0.0226% | $91.31 | $1.01M | +2.91% | |
| 2024-08-09 | Sale | Jacobson Mark L. | Chief Operating Officer | 47,739 0.1009% | $84.26 | $4.02M | +11.41% | |
| 2024-05-29 | Sale | Coleman Mark | director | 5,248 0.011% | $75.14 | $394,333 | +19.59% | |
| 2024-05-29 | Sale | Jacobson Mark L. | Chief Operating Officer | 7,910 0.0165% | $74.31 | $587,813 | +19.59% | |
| 2024-05-28 | Sale | Coleman Mark | director | 5,249 0.0108% | $75.21 | $394,775 | +17.14% | |
| 2024-04-01 | Sale | Jacobson Mark L. | Chief Operating Officer | 24,662 0.0522% | $77.24 | $1.9M | +14.29% | |
| 2024-03-15 | Sale | JEFFS ROGER | director | 2,347 0.0047% | $71.61 | $168,062 | +15.50% | |
| 2024-03-14 | Sale | JEFFS ROGER | director | 16,976 0.036% | $69.70 | $1.18M | +25.01% | |
| 2023-09-15 | Sale | Coleman Mark | director | 29,588 0.0626% | $75.18 | $2.22M | +1.06% | |
| 2021-11-19 | JEFFS ROGER | director | 3,950 0.0109% | $37.30 | $147,350 | +3.44% | ||
| 2021-11-18 | Coleman Mark | director | 1,430 0.0037% | $35.09 | $50,181 | +4.03% | ||
| 2021-11-18 | Pizzie Nick | CHIEF FINANCIAL OFFICER | 955 0.0025% | $35.26 | $33,676 | +4.03% | ||
| 2021-11-17 | Saad Mark E | director | 3,300 0.0087% | $34.52 | $113,922 | +7.00% | ||
| 2021-05-12 | Coleman Mark | director | 500 0.0014% | $58.15 | $29,075 | -38.38% | ||
| 2020-06-29 | Coleman Mark | director | 650 0.0018% | $78.50 | $51,025 | -5.10% | ||
| 2020-06-29 | Pizzie Nick | Chief Financial Officer | 777 0.0021% | $76.64 | $59,549 | -5.10% | ||
| 2019-09-26 | Pizzie Nick | Chief Financial Officer | 2,180 0.0063% | $24.80 | $54,064 | +210.19% | ||
| 2019-06-26 | Coleman Mark | director | 15,800 0.0481% | $23.10 | $364,980 | +145.30% |
Total: 28
*Gray background shows transactions not older than one year
Insider Historical Profitability
51.12%
| Pizzie Nick | Chief Financial Officer | 42187 0.0865% | $5.26M | 6 | 2 | +84.72% |
| Coleman Mark | director | 14600 0.0299% | $1.82M | 7 | 3 | +51.01% |
| Saad Mark E | director | 10002 0.0205% | $1.25M | 2 | 1 | +23.86% |
| JEFFS ROGER | director | 120756 0.2476% | $15.07M | 1 | 2 | +3.44% |
| Kaye Randall | Chief Medical Officer | 6022 0.0123% | $751,304.72 | 1 | 0 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$159,914,414 | 243 | 18.52% | $5.96B | |
$211,610,344 | 91 | 38.45% | $7.48B | |
$52,263,649 | 70 | 1.18% | $4.42B | |
$108,876,545 | 67 | 72.81% | $7.7B | |
$42,463,802 | 57 | 17.85% | $7.14B |
AXSM Institutional Investors: Active Positions
| Increased Positions | 154 | +47.68% | 5M | +13.34% |
| Decreased Positions | 136 | -42.11% | 6M | -15.41% |
| New Positions | 62 | New | 2M | New |
| Sold Out Positions | 40 | Sold Out | 2M | Sold Out |
| Total Postitions | 341 | +5.57% | 38M | -2.07% |
AXSM Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Rtw Investments, Lp | $493,902.00 | 8.27% | 4.05M | -138,192 | -3.3% | 2024-12-31 |
| Vanguard Group Inc | $475,751.00 | 7.96% | 3.9M | -92,866 | -2.32% | 2024-12-31 |
| Blackrock, Inc. | $430,756.00 | 7.21% | 3.53M | +135,015 | +3.97% | 2024-12-31 |
| Fairmount Funds Management Llc | $179,084.00 | 3% | 1.47M | -891,094 | -37.76% | 2024-12-31 |
| Bvf Inc/Il | $169,219.00 | 2.83% | 1.39M | +342,064 | +32.7% | 2024-12-31 |
| Fmr Llc | $121,964.00 | 2.04% | 1M | -87,641 | -8.05% | 2024-12-31 |
| Ra Capital Management, L.P. | $121,910.00 | 2.04% | 1M | 0 | 0% | 2024-12-31 |
| Macquarie Group Ltd | $117,527.00 | 1.97% | 964,047 | -31,240 | -3.14% | 2024-12-31 |
| State Street Corp | $115,479.00 | 1.93% | 947,251 | +30,443 | +3.32% | 2024-12-31 |
| Geode Capital Management, Llc | $111,248.00 | 1.86% | 912,538 | +4,079 | +0.45% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.